Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model

Nuclear Medicine Communications

Volumn 28, Issue 2, 2007, Pages 129-133

  Kinuya, Seigo ^a   Yokoyama, Kunihiko ^a   Fukuoka, Makoto ^a   Hiramatsu, Takashi ^a   Mori, Hirofumi ^a   Shiba, Kazuhiro ^b   Watanabe, Naoto ^b   Shuke, Noriyuki ^b   Michigishi, Takatoshi ^b   Tonami, Norihisa ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adjuvant therapy; Colon cancer; Intraperitoneal radioimmunotherapy; Monoclonal antibody; Peritoneal carcinomatosis

Indexed keywords

FLUOROURACIL; IMMUNOGLOBULIN G1 ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A 7 IODINE 131; RADIOPHARMACEUTICAL AGENT; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER SURVIVAL; CELL KILLING; COLON CANCER; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; INOCULATION; ISOTOPE LABELING; NONHUMAN; PERITONEUM METASTASIS; RADIOIMMUNOTHERAPY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 33845974893     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328013e5a8     Document Type: Article

References (28)

1. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43:1341-1346.
2. Chau I, Cunningham D. Adjuvant therapy in colon cancer - what, when and how? Ann Oncol (in press) (Published online Mar 8, 2006; DOI:10.1093/annonc/mdl029).
3. Markman M. Intraperitoneal chemotherapy in the management of colon cancer. Semin Oncol 1999; 26:536-539.
4. Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-3419.
5. Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, et al Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8:1941-1950.
6. Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996; 37:1491-1496.
7. Buijs WC, Tibben JG, Boerman OC, Molthoff CF, Massuger LF, Koenders EB, et al. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 1998; 25:1552-1561.
8. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm 2000; 15:53-64.
9. Quadri SM, Malik AB, Chu HB, Freedman RS, Vriesendorp HM. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med 1996; 37:1545-1551.
10. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, et al. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci 2003; 94:650-654.
11. 131I-counterpart. Cancer Lett 2005; 219:41-48.
12. Fujimori K, Furudate M. Dosimetry and radiation dose distribution in tumors for radioimmunotherapy: the effect of tumor size. Kaku Igaku 1994; 31:241-248.
13. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
14. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005; 24:539-567.
15. 131I-labeled monoclonal antibodies. Cancer Res 1992; 52:6036-6044.
16. Kotanagi H, Takahashi T, Masuko T, Hashimoto Y, Koyama K. A monoclonal antibody against human colon cancers. Tohoku J Exp Med 1986; 148:353-360.
17. Kinuya S, Kawashima A, Yokoyama K, Koshida K, Konishi S, Watanabe N, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med 2002; 43:1084-1089.
18. Kinuya S, Yokoyama K, Konishi S, Hiramatsu T, Watanabe N, Shuke W, et al. Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model. Jpn J Cancer Res 2000; 91:573-578.
19. Li XF, Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, et al. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging 2002; 29:1669-1674.
20. Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur J Nucl Med Mol Imaging 2004; 31:981-985.
21. Kinuya S, Yokoyama K, Tega H, Hiramatsu T, Konishi S, Watanabe N, et al. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts. J Cancer Res Clin Oncol 1999; 125:630-636.
22. Sato N, Saga T, Sakahara H, Yao Z, Nakamoto Y, Zhang M, et al. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J Nucl Med 1999; 40:685-692.
23. 2H nuclear magnetic resonance studies. Cancer Res 1991; 51:3289-3295.
24. Hall E. Radiobiology for the Radiologist, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2000.
25. Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 2001; 7:192-201.
26. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002; 94:1332-1348.
27. Yokoyama K, Carrasquillo JA, Chang AE, Colcher D, Roselli M, Sugarbaker P, et al. Differences in biodistribution of indium-111- and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 1989; 30:320-327.
28. Kinuya S, Jeong JM, Garmenstani K, Saga T, Camera L, Brechbiel MW, et al. Effect of metabolism on retention of indium-III-labeled monoclonal antibody in liver and blood. J Nucl Med 1994; 35:1851-1857.